at 08:05 Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial ... With the news, HealthTap is... Astria Therapeutics, Inc. , a biopharmaceutical company focused on developing ...

Viasat, Inc. , a global communications company, today announced the launch of its innovative home and mobile broadband service in Mexico. Viasat, in collaboration with Altán, the Mexican ...

AstraZeneca (AZN) and Daiichi Sankyo have submitted a new Biologics License Application for accelerated approval in the US for datopotamab deruxtecan for the treatment of adult patients with locally ...

Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

The ROS-1 NSCLC current market is mainly dominated by tyrosine kinase inhibitors such as XALKORI at present and is anticipated to be dominated ...

Tokyo District Court on Wednesday sentenced a former employee of drugmaker Daiichi Sankyo to 16 years in prison for the murder of his wife by methanol poisoning in 2022. Presiding Judge Iichiro ...

New Delhi, The Delhi High Court on Tuesday ordered auctioning of the Fortis trademark in connection with the ₹3,500 crore arbitral award passed in favour of Japanese pharma major Daiichi Sankyo ...

NEW YORK – AstraZeneca and Daiichi Sankyo on Wednesday said they have begun three new Phase III trials to test the activity of the Trop2-targeted antibody-drug conjugate datopotamab deruxtecan ...